Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fb0b2ec1c62686bd1f63f161596afee |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2560-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4753 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-483 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 |
filingDate |
2016-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fbee97e83ab572e81eb31eaf2614c15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d4f8a3640ee7ea57ab62b9227ac9bba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cf4efa652fead182f929d0c6a2d9fe4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1459aeca26f85d7542430a55ad7596e5 |
publicationDate |
2018-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2016325715-A1 |
titleOfInvention |
Quantifying Met protein for cancer treatment |
abstract |
Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient. |
priorityDate |
2015-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |